{"id":"hcp1904-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL299613","moleculeType":"Small molecule","molecularWeight":"302.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HCP1904-2 activates glucagon-like peptide-1 (GLP-1) receptors on pancreatic beta cells and alpha cells, stimulating glucose-dependent insulin secretion while suppressing glucagon secretion. The long-acting formulation provides sustained receptor activation, enabling less frequent dosing while maintaining therapeutic glucose control. This mechanism also promotes satiety and may support weight loss in patients with type 2 diabetes.","oneSentence":"HCP1904-2 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:47:40.373Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04830449","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2020-10-29","conditions":"Hypertension","enrollment":122}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HCP1904-2","genericName":"HCP1904-2","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HCP1904-2 is a treatment being studied in a Phase III clinical trial for essential hypertension. The trial, NCT04830449, is evaluating the efficacy and safety of HCP1904-2 compared to an active control in patients with hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}